Q3 2018 EPS Estimates for Unum Therapeutics Inc Cut by Analyst (UMRX)
Unum Therapeutics Inc (NASDAQ:UMRX) – Equities research analysts at SunTrust Banks reduced their Q3 2018 earnings per share estimates for Unum Therapeutics in a report issued on Monday, August 13th. SunTrust Banks analyst P. Lawson now anticipates that the company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of ($0.29). SunTrust Banks has a “Buy” rating and a $21.00 price objective on the stock. SunTrust Banks also issued estimates for Unum Therapeutics’ Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.40) EPS, FY2019 earnings at ($1.39) EPS, FY2020 earnings at ($1.54) EPS, FY2021 earnings at ($1.38) EPS and FY2022 earnings at ($1.54) EPS.
Several other research firms have also weighed in on UMRX. Wedbush upped their price objective on Unum Therapeutics from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday. Morgan Stanley assumed coverage on Unum Therapeutics in a research note on Monday, April 23rd. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, Cowen assumed coverage on Unum Therapeutics in a research note on Monday, April 23rd. They issued a “market perform” rating on the stock.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings data on Monday, August 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.67 million during the quarter, compared to the consensus estimate of $2.45 million.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in Unum Therapeutics during the 2nd quarter worth approximately $177,000. Spark Investment Management LLC bought a new stake in Unum Therapeutics during the 2nd quarter worth approximately $186,000. Wasatch Advisors Inc. grew its position in Unum Therapeutics by 5.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock worth $3,840,000 after acquiring an additional 13,525 shares during the last quarter. Keybank National Association OH bought a new stake in Unum Therapeutics during the 2nd quarter worth approximately $195,000. Finally, Athanor Capital LP bought a new stake in Unum Therapeutics during the 1st quarter worth approximately $248,000. Institutional investors and hedge funds own 47.62% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.